According to Cache Valley Daily, around 60% of Utah's medicinal cannabis users obtain their cannabis from sources other than the state's authorized market. The study, done by Cannabis Public Policy Consulting (CPPC) on behalf of the Utah Department of Agriculture and Food (UDAF), sheds light on accessibility issues in the state's medicinal cannabis program.
A 2020 analysis published in Science magazine revealed a striking disparity in cannabis research funding. Of the $1.56 billion directed to the topic between 2000 and 2018 in the United States, Canada, and the United Kingdom, roughly half was spent on investigating the potential harms and adverse effects of recreational cannabis use. The U.S. National Institute on Drug Abuse (NIDA), the largest funder, allocated more money to studying cannabis misuse and its negative consequences than to exploring the therapeutic potential of cannabis and its derived compounds.
The United States Hemp Authority is working to assure the quality of Delta-8 THC through an upcoming certification procedure. This effort intends to set stringent standards and promote self-regulation in the Delta-8 sector, which is subject to relatively lenient regulatory scrutiny.
Except for vape and smokable variants, there are no designated age restrictions for CBD usage. At the federal level, there exists no age threshold for CBD consumption. While hemp-derived CBD products (with less than 0.03% THC) are lawful nationwide, certain states may necessitate individuals to be either 18 or 21 to procure them. An array of options persists, including gummies, honey sticks, and oils.
Of the hemp samples tested, approximately 93% exceeded the federal 0.3% limit, and nearly half of the provided online documents from manufacturers differed from the corresponding product labels. In a comparison between NIST results and online documentation for 22 samples, researchers observed discrepancies of approximately 55% for total Δ9-THC, 68% for THCA, and 18% for Δ9-THC.
MMJ BioPharma's noble pursuit of scientific advancement has been met with a series of inexplicable roadblocks and bureaucratic hurdles erected by the DEA. In 2018, the company dutifully applied for the necessary licenses to cultivate marijuana for research and development purposes, eagerly anticipating the opportunity to commence clinical trials that could yield life-changing treatments. Yet, despite meticulously following the DEA's convoluted application process, MMJ BioPharma found itself trapped in a seemingly endless cycle of delays, obfuscation, and stonewalling.
A case report authored by researchers from the Department of Psychiatry and Psychology at the Cleveland Clinic's Center for Behavioral Health, Neurological Institute in Ohio, looks into the potential benefits of psilocybin for color blindness.
A fascinating new poll conducted by NuggMD, a medical marijuana telehealth company, suggests cannabis consumers are growing wise to these panderous tricks. The survey of likely voters who regularly use marijuana found that party affiliation takes a back seat for this voting bloc. A solid majority - 59% - said they would vote for a pro-cannabis candidate regardless of party. Only 14% were locked into voting along party lines.
A Republican senator is pushing back against a recent policy change by U.S. Customs and Border Protection (CBP) that reduced the term of ineligibility for work due to past marijuana use from two years to three months. The senator doubts the trustworthiness of recruits who have used cannabis and believes that this move jeopardizes the safety and integrity of Border Patrol agents.
"Many adolescents partake in sporadic cannabis use, with non-problematic usage being significantly more common than instances of Cannabis Use Disorder," the authors emphasize. "Hence, it's imperative to scrutinize the neurocognitive and psychological ramifications among adolescents escalating to heavier cannabis use and those maintaining minimal consumption."